20 Nov AGM 11:30am, page-22

Don't ask questions which are commercially sensitive as you won't get an answer (don't ask any questions about partnership talks or their progress) and don't ask questions that can be answered vaguely or all you will get is a vague answer. Here are two very specific questions you could ask that should get a yes or no answer.

1. Has all the data analysis of the BIT-009 trial been completed and will all of this data be released to the market at the time of the November conference? If not, when will the complete data be released?

2. MM having seen the data from the BIT-009 trial, in your opinion will BIT need to run another phase 2 trial before being in a position running a phase 3 trial? Is there any extra clinical data required before moving to phase 3?